These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8300892)

  • 1. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine.
    Kohl RL; Sandoz GR; Reschke MF; Calkins DS; Richelson E
    J Clin Pharmacol; 1993 Nov; 33(11):1092-103. PubMed ID: 8300892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
    Zhang LL; Liu HQ; Yu XH; Zhang Y; Tian JS; Song XR; Han B; Liu AJ
    CNS Neurosci Ther; 2016 Aug; 22(8):715-22. PubMed ID: 27160425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomic function and plasma catecholamines following stressful sensory stimuli.
    Kohl RL
    Aviat Space Environ Med; 1993 Oct; 64(10):921-7. PubMed ID: 8240196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests.
    Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD
    Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy of ginger with various antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME
    Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxepin's effects on chronic pain and depression: a controlled study.
    Hameroff SR; Weiss JL; Lerman JC; Cork RC; Watts KS; Crago BR; Neuman CP; Womble JR; Davis TP
    J Clin Psychiatry; 1984 Mar; 45(3 Pt 2):47-53. PubMed ID: 6321454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.